• Alvotech entered a long-term manufacturing partnership with LOTTE Biologics to expand US-based production and global biosimilar supply.
• LOTTE Biologics will make drug substance for multiple antibody biosimilars at its Syracuse, New York facility for worldwide distribution.
• The site provides 40,000 liters of bioreactor capacity, adding to Alvotech’s manufacturing network to support demand over the next decade.
• Commercial supply depends on successful technology transfer, manufacturing qualification, and required regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061630OMX_____CNEWS_EN_GNW1001276638_en) on October 06, 2026, and is solely responsible for the information contained therein.